Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ ...
News Medical on MSN5h
Triple therapy shows strong response in BRAF V600E mutant metastatic colorectal cancerPatients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback